Relative risk of end-stage renal disease requiring dialysis in treated ankylosing spondylitis patients compared with individuals without ankylosing spondylitis: A nationwide, population-based, matched-cohort study

• Published in: PloS one 2020-04, Vol.15 (4), p.e0231458-e0231458
• Main Authors: Chen, Hsin-Hua, Lin, Ching-Heng, Lai, Kuo-Lung, Hsieh, Tsu-Yi, Chen, Yi-Ming, Tseng, Chih-Wei, Gotcher, Donald F, Chang, Yu-Mei, Chiou, Chuang-Chun, Liu, Shih-Chia, Weng, Shao-Jen
• Format: Article
• Language: English
• Subjects: Age; Ambulatory care; Aminoglycosides; Amphotericin B; Ankylosing spondylitis; Antifungal agents; Biology and Life Sciences; Cisplatin; Cohort analysis; Confidence intervals; Contrast agents; Corticosteroids; COX-2 inhibitors; Creatinine; Cyclooxygenase-2; Diabetes; Diabetes mellitus; Dialysis; Drug dosages; End-stage renal disease; Health hazards; Health insurance; Health risks; Hemodialysis; Hospitals; Hypertension; IgA nephropathy; Immunoglobulin A; Immunology; Industrial engineering; Internal medicine; Kidney diseases; Laboratories; Matching; Medical records; Medical research; Medicine; Medicine and Health Sciences; Methotrexate; Nonsteroidal anti-inflammatory drugs; Personal information; Population; Population studies; Population-based studies; Quality of life; Renal failure; Rheumatology; Risk analysis; Risk factors; Sex; Statistical models; Studies; Sulfasalazine
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0231458

To examine the relative risk of end-stage renal disease (ESRD) requiring dialysis among treated ankylosing spondylitis (AS) patients compared with non-AS individuals. We used claims data from Taiwan's National Health Insurance Research Database obtained between 2003 and 2012, and enrolled 37,070 newly treated AS patients and randomly selected 370,700 non-AS individuals matched (1:10) for age, sex and year of index date. Those with a history of chronic renal failure or dialysis were excluded. After adjusting for age, sex, diabetes mellitus, hypertension, IgA nephropathy, frequency of serum creatinine examinations, use of methotrexate, sulfasalazine, ciclosporis, corticosteroid, aminoglycoside, amphotericin B, cisplatin, contrast agents and annual cumulative defined daily dose (cDDD) of traditional NSAIDs, selective cyclooxygenase-2 inhibitors (COX-2i) and preferential COX-2i, we calculated the adjusted hazard ratios (aHRs) with 95% confidence intervals using the Cox proportional hazard model to quantify the risk of ESRD in AS patients. We re-selected 6621 AS patients and 6621 non-AS subjects by further matching (1:1) for cDDDs of three groups of NSAIDs to re-estimate the aHRs for ESRD. Fifty-one (0.14%) of the 37,070 AS patients and 1417 (0.38%) of the non-AS individuals developed ESRD after a follow-up of 158,846 and 1,707,757 person-years, respectively. The aHR for ESRD was 0.59 (0.42-0.81) in AS patients compared with non-AS individuals. However, after further matching for cDDD of NSAIDs, the aHR of ESRD was 1.02 (0.41-2.53). Significant risk factors included hypertension, IgA nephropathy and use of COX-2i. The risk of ESRD was not significantly different between treated AS patients and non-AS individuals matched for age, sex, year of index date and dose of NSAID.